London, United Kingdom — A new COVID-19 variant, known informally as “razor blade throat” COVID, is emerging as a cause for concern in several regions, notably the eastern Mediterranean and Southeast Asia. This variant, referred to scientifically as NB.1.8.1. or “Nimbus,” is linked to reports of particularly painful sore throats among infected individuals.
Medical professionals in the UK, India, and other countries have highlighted throat discomfort as a common symptom associated with Nimbus. While COVID-19 symptoms can vary widely, they typically include fever, chills, coughing, shortness of breath, and loss of taste or smell. However, experts suggest the public should remain calm, as current evidence does not indicate that Nimbus poses a greater health risk than previous variants.
The World Health Organization (WHO) reported an uptick in COVID-19 cases related to this variant as of late May. Statistics show that Nimbus constituted nearly 11% of global sequenced samples reported mid-month. This variant has been detected among travelers arriving in various states in the U.S., including California, Washington, Virginia, and New York, through airport screenings.
Notably, the WHO has emphasized that existing COVID-19 vaccines remain effective against Nimbus. Classifying it as a “variant under monitoring,” the organization assessed the public health risk at a low level globally. Experts advocate for continued vaccination efforts, even as health guidelines evolve and adapt to emerging variants.
In a recent development, U.S. Health Secretary Robert F. Kennedy Jr. announced that COVID-19 vaccinations are no longer recommended for healthy children and pregnant women, a decision that has sparked debate among public health professionals. Critics argue that such guidance could undermine efforts to maintain community immunity during a time when variants like Nimbus are circulating.
Healthcare authorities continue to stress the importance of monitoring symptoms and seeking medical advice when necessary. As more information becomes available, ongoing vigilance regarding COVID-19 variants remains crucial to safeguarding public health.